Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

I Widengård, O Mäepea, A Alm

Abstract

Aim—To investigate the effect on intraocular pressure (IOP) and aqueous flare of topical applications of latanoprost and dipivefrin alone or combined.

Methods—22 patients with open angle glaucoma or ocular hypertension were included in a 4 week open label study. Median age was 68 years (range 50–79). They were allocated to either 2 weeks’ treatment with once daily evening administration of latanoprost monotherapy (50 µg/ml) or twice daily dipivefrin monotherapy (1 mg/ml), followed by 2 weeks’ combination therapy with both drugs.

Results—Latanoprost alone reduced IOP from 19.3 (SD 1.4) to 14.8 (0.9) mm Hg (p<0.01). Addition of dipivefrin caused a further reduction to 12.4 (0.9) mm Hg (p<0.01 compared with latanoprost alone). In the group where the treatment started with dipivefrin IOP was reduced from 22.3 (1.2) to 18.4 (1.0) mm Hg (p<0.01) with the combination to 14.9 (0.9) mm Hg (p<0.01). No change in aqueous flare was observed with either drug, alone or in combination. A slight increase in conjunctival hyperaemia was observed when the two drugs were combined.

Conclusions—Latanoprost and dipivefrin have an additive effect on IOP and no clinically significant effect on the permeability to proteins of the blood-aqueous barrier. This implies that the two drugs can be a useful combination for the treatment of glaucoma.

(Br J Ophthalmol 1998;82:404–406)

Latanoprost, a prostaglandin F₂α analogue has recently been introduced as an ocular hypotensive agent. Recent large studies have shown it to be a potent agent in patients with glaucoma or ocular hypertension. It has also been suggested that the ocular hypotensive effect of adrenaline may be at least partly mediated by an endogenous production of prostaglandins. Thus, both from a theoretical and a clinical point of view it would be of interest to determine the effect on intraocular pressure (IOP) of the combination of a prostaglandin analogue and an adrenergic agonist.

A further reason to study this combination is the possibility that the two drugs combined could have an effect on the permeability of the blood-aqueous barrier. In the rabbit low doses of naturally occurring prostaglandins reduce IOP while high doses cause an increased IOP with a breakdown of the blood-aqueous barrier. The eyes of cats and monkeys are much more resistant and a similar breakdown of the blood-aqueous barrier was not observed even after repeated topical application of prostaglandins. In previous clinical studies latanoprost monotherapy had no effect on aqueous flare. Adrenergic agonists may also affect the permeability of the blood-aqueous barrier. Thus chronic stimulation of the sympathetic nerves in rabbits causes a breakdown of the blood-aqueous barrier that seems to be mediated by prostaglandins. A small prostaglandin mediated increase in the blood-aqueous barrier permeability to sodium fluorescein was reported after treatment with adrenaline for 2 months or more in human eyes, and Araie et al reported a biphasic response of the blood-aqueous barrier in human eyes to a single dose of phenylephrine; an initial marked increase in aqueous flare followed by a decrease. The present study was performed to evaluate the effect of latanoprost and dipivefrin, either individually or in combination, on IOP and on the blood-aqueous barrier in patients with open angle glaucoma or ocular hypertension.

Materials and methods

This was a 4 week open label randomised study. The study protocol was approved by the Swedish regulatory authority and the local ethics committee. The study was performed in accordance with the revised Declaration of Helsinki (Hong Kong 1989). Each patient gave written informed consent before entry into the study.

Patients with unilateral or bilateral open angle glaucoma, capsular glaucoma, or ocular hypertension (a prestudy IOP of at least 22 mm Hg) were included. If both eyes fulfilled the eligibility criteria, the right eye was designated as the study eye. There was a washout period of previous treatment in the study eye of 2 weeks for adrenergic agonists, 5 days for cholinergic agonists or oral carbonic anhydrase inhibitors, and 3 weeks for β adrenergic blockers.

Exclusion criteria included an IOP of >35 mm Hg on current treatment, concomitant medication known to affect IOP, pregnancy, a history of acute angle closure, or severe dry eye syndrome, intraocular surgery or argon laser trabecuoplasty within the previous 6 months, current use of contact lenses, ocular inflammation/infection within the previous 15
† Treatment was initiated with dipivefrin.

* Group that started with latanoprost with dipivefrin added after 2 weeks’ treatment.

---

### Table 1 Patient demographics

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Day 0</th>
<th>Day 14</th>
<th>Day 21</th>
<th>Day 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lat/Dip</td>
<td>69 (50–79)</td>
<td>68 (60–74)</td>
<td>68 (50–79)</td>
<td></td>
</tr>
<tr>
<td>Dip/Lat</td>
<td>8/3</td>
<td>7/4</td>
<td>15/7</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td>POAG</td>
<td>8</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Capsular glaucoma</td>
<td>1</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>OH</td>
<td>2</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Previous glaucoma treatment</td>
<td>11</td>
<td>9</td>
<td>20</td>
<td></td>
</tr>
</tbody>
</table>

* Group that started with latanoprost with dipivefrin added after 2 weeks’ treatment.
† Treatment was initiated with dipivefrin.

### Table 2 IOP (mean (SEM)) at baseline and after 2, 3, and 4 weeks’ treatment for patients who started treatment with latanoprost (Lat/Dip) or dipivefrin (Dip/Lat)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Day 0</th>
<th>Day 14</th>
<th>Day 21</th>
<th>Day 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lat/Dip</td>
<td>19.3 (1.4)</td>
<td>14.8 (0.9)</td>
<td>12.1 (0.9)</td>
<td>12.4 (0.9)</td>
</tr>
<tr>
<td>Dip/Lat</td>
<td>22.3 (1.2)</td>
<td>18.4 (1.0)</td>
<td>13.2 (0.7)</td>
<td>14.9 (0.9)</td>
</tr>
</tbody>
</table>

### Table 3 Aqueous flare as photon counts (mean (SEM)) at baseline and after 2, 3, and 4 weeks’ treatment for patients who started treatment with latanoprost (Lat/Dip) or dipivefrin (Dip/Lat)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Day 0</th>
<th>Day 14</th>
<th>Day 21</th>
<th>Day 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lat/Dip</td>
<td>10.4 (1.1)</td>
<td>8.6 (1.0)</td>
<td>9.8 (1.1)</td>
<td>9.6 (1.3)</td>
</tr>
<tr>
<td>Dip/Lat</td>
<td>7.4 (1.1)</td>
<td>7.2 (0.8)</td>
<td>7.4 (0.9)</td>
<td>7.2 (0.6)</td>
</tr>
</tbody>
</table>

### Table 4 Hyperaemia score (mean (SEM)) obtained by comparing with a set of standard photographs from none (0) to severe (3) at baseline and after 2, 3, and 4 weeks’ treatment for patients who started treatment with latanoprost (Lat/Dip) or dipivefrin (Dip/Lat)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Day 0</th>
<th>Day 14</th>
<th>Day 21</th>
<th>Day 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lat/Dip</td>
<td>0.59 (0.12)</td>
<td>0.64 (0.14)</td>
<td>0.95 (0.16)</td>
<td>1.00 (0.20)</td>
</tr>
<tr>
<td>Dip/Lat</td>
<td>0.45 (0.13)</td>
<td>0.59 (0.16)</td>
<td>1.00 (0.18)</td>
<td>1.18 (0.19)</td>
</tr>
</tbody>
</table>

---

**Results**

Twenty two patients were included in the study, all of whom completed the 4 week treatment period. The demographic characteristics of the study population are shown in Table 1. In general, there were no major differences in patient characteristics between the two treatment groups. Even though the patients were assigned randomly there was a difference in IOP at baseline (day 0) between treatment groups of 3 mm Hg.

Table 2 presents the IOP for each examination in the two treatment groups. Latanoprost alone reduced morning IOP with 4.5 (1.2) mm Hg (p<0.01) from 19.3 mm Hg. Adding dipivefrin caused a further reduction of 2.3 (0.6) mm Hg on day 28 (p<0.01). Combined, the two drugs reduced IOP with 6.9 mm Hg (35%, p<0.0001) on day 28.

Dipivefrin alone reduced morning IOP with 3.9 (1.1) mm Hg (p<0.01) from 22.3 mm Hg. Adding latanoprost caused a further reduction of 3.6 (0.5) mm Hg on day 28 (p<0.0001). In this group the two drugs combined caused an IOP reduction from baseline of 7.4 mm Hg (33%, p<0.0001).

Table 3 presents photon count values. In each group the highest mean values were observed on baseline and neither drug, alone or combined, caused a significant change in flare values. Compared with baseline, flare values on day 28 were increased in seven patients, unchanged in two, and decreased in 13 patients with a range from an increase of 6.5 photon counts to a reduction of 7.1. In addition, slit lamp evaluation of flare and cells revealed no clinically significant effects of treatment.

Hyperaemia scores are presented in Table 4. At baseline mean hyperaemia was graded between none and mild, and no change occurred when either drug was applied alone. With the two drugs combined the hyperaemia score almost doubled (p<0.05), but the average hyperaemia was still judged to be mild. Moderate hyperaemia, grade 2, was observed in five of 22 patients on the last examination.

No change in refraction or visual acuity was observed. Mild punctate corneal erosions were observed in two eyes on day 28; one untreated eye and one that had been treated with dipivefrin for 4 weeks with latanoprost added for the last 2 weeks.

**Discussion**

A majority of the patients included in this study had a diagnosis of open angle glaucoma.
There was no lower IOP limit for inclusion of patients with established glaucoma, and the mean baseline IOP in the two groups was only 19 and 22 mm Hg respectively. One can expect less effect on IOP, both in absolute and relative terms, with a low initial IOP. Still, both latanoprost and dipivefrin caused statistically highly significant reductions in IOP when applied alone. Moreover, a statistically significant further reduction in IOP was observed when the two drugs were combined for the last 14 days of the study with an added reduction of 16% for dipivefrin and 19% for latanoprost. These results do not indicate that a possible prostaglandin mediated effect of adrenaline, as reported by Camras et al., diminishes the effect of latanoprost. A solution of 50 µg/ml is at the top of the dose-response curve for latanoprost. Prostaglandin effects are mediated by a family of receptors and latanoprost is a rather selective agonist for one of them, the EP2 receptor. Thus, in the event that prostaglandin receptors are involved in the ocular hypotensive effect of adrenaline one may speculate that other prostaglandin receptors than the EP2 receptor are involved.

An additive effect of 19% when latanoprost is added to dipivefrin is of clinical interest since the number of clinically useful combinations including dipivefrin is limited; a reduction of IOP of 20% or more can mainly be expected by adding a full dose of acetazolamide, judged from early experience of combining adrenaline and acetazolamide. The effect of adding dipivefrin to timolol results, as expected, in only a small or no additive effect on IOP, while combining dipivefrin and pilocarpine can only be expected to give a modest additive effect; the effect of combining 2% pilocarpine and 1% adrenaline resulted in an IOP that was 12% lower than with pilocarpine alone. Neither latanoprost nor dipivefrin, alone or combined, caused any increase in flare as evaluated with the laser flare meter. Previous studies with quantitative evaluation of flare have not shown any effect for either latanoprost or adrenaline, but a slight increase in the permeability of the blood-aqueous barrier to fluorescein was observed after 2 months’ treatment with adrenaline in human eyes. This effect seemed to be mediated by prostaglandins since it was prevented by indomethacin. Fluorescein is a small molecule that normally passes through the blood-aqueous barrier slowly and the change in the barrier permeability necessary to cause a slight increase in fluorescein permeation is probably of no clinical relevance. It is also unlikely that the effect is mediated by the EP2 receptor. In rabbits prostaglandin induced breakdown of the blood-aqueous barrier occurs mainly with agents that have a high affinity for the EP2 receptor, and EP receptor agonists do not disrupt the barrier. As latanoprost has little or no affinity for the EP2 receptor it is not surprising that we found no effect on aqueous flare.

Both latanoprost and dipivefrin were very well tolerated either alone or in combination. A slight increase in conjunctival hyperaemia was observed in some patients following combination treatment. However, this was mild and did not require the cessation of treatment.

In conclusion, one can expect latanoprost and dipivefrin reduced IOP effectively in patients with open angle glaucoma or ocular hypertension. Whether given alone or in combination they had no measurable effect on the permeability of the blood-aqueous barrier to proteins. Moreover, the combination of latanoprost and dipivefrin had an additive effect on IOP reduction and was well tolerated. This implies that the combination of latanoprost and dipivefrin should prove an effective and safe addition to the current treatment options for glaucoma.
Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

I Widengård, O Mäepea and A Alm

doi: 10.1136/bjo.82.4.404

Updated information and services can be found at:
http://bjo.bmj.com/content/82/4/404

These include:

**References**

This article cites 22 articles, 3 of which you can access for free at:
http://bjo.bmj.com/content/82/4/404#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

Angle (1006)
Glaucoma (988)
Intraocular pressure (1002)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/